News & Analysis as of

New Legislation › Regulatory Oversight › Innovation

Bracewell LLP

Balancing Innovation and Oversight: Federal AI Policy in Transition

Bracewell LLP on

Consistent with their broader policy differences, the Trump and Biden administrations can be characterized by their notably divergent approaches to regulating artificial intelligence (AI). Indeed, a recent White House...more

Jackson Lewis P.C.

The Potential For One Long Moratorium on AI Regulation

Jackson Lewis P.C. on

The federal budget bill titled One Big Beautiful Bill aims to unharness artificial intelligence (AI) development in the U.S. The current draft of the bill, which has passed the House, proposes a 10-year moratorium on the...more

Benesch

The Year In AI: 2024 Roundup and Forward-Looking Guidance From the Benesch AI Commission

Benesch on

It was a busy year for AI in 2024, and the Benesch AI Commission continued to follow the headlines and stay on top of legal developments. We wanted to take a look back at the year while also looking forward with some...more

Ballard Spahr LLP

CFPB and Utah AG announce joint office hours in Salt Lake City as part of ACFIN

Ballard Spahr LLP on

The CFPB and Utah AG’s Office have announced that they will hold the first joint office hours as part of the American Consumer Financial Innovation Network (ACFIN).  The joint office hours will be held on January 30, 2020 in...more

Akin Gump Strauss Hauer & Feld LLP

Kentucky Adopts First Legislation Creating an InsurTech Innovation “Sandbox.”

Akin Gump Strauss Hauer & Feld LLP on

Kentucky House Bill 386 is the first comprehensive framework for an insurance regulatory “sandbox” in the nation. It allows companies, even those without an insurance license, to market their inventions in a tailored...more

Hogan Lovells

There'll Be Some Changes Made: President Signs Prescription Drug and Biologic User Fee Reauthorization Act

Hogan Lovells on

On August 18, 2017, President Trump signed into law the FDA Reauthorization Act (FDARA). FDARA reauthorizes user fees paid to FDA to support regulatory review of innovator drugs and biologics, medical devices, generic drugs,...more

6 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide